Loading...
Loading...
MLTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 13.0M |
| Operating I/L | -13.0M |
| Other Income/Expense | 1.4M |
| Interest Income | 0.0M |
| Pretax | -11.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -9.4M |
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of Sonelokimab, a novel investigational Nanobody therapy designed to treat inflammation. The company is currently focused on conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. MoonLake Immunotherapeutics generates revenue through the development and potential commercialization of innovative therapies aimed at addressing unmet medical needs in the field of inflammation treatment.
